Oncolytic Virus Immunotherapy
Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. Thi...
Saved in:
| HerausgeberIn: | |
|---|---|
| Sonstige: | |
| Year of Publication: | 2022 |
| Language: | English |
| Physical Description: | 1 electronic resource (366 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993544933204498 |
|---|---|
| ctrlnum |
(CKB)5680000000037759 (oapen)https://directory.doabooks.org/handle/20.500.12854/81172 (EXLCZ)995680000000037759 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
Marchini, Antonio edt Oncolytic Virus Immunotherapy Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (366 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, “Oncolytic Virus Immunotherapy”, summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities. English Medicine bicssc Clinical & internal medicine bicssc oncolytic viruses melanoma immunotherapy checkpoint inhibitors combinatory therapy reovirus oncolytic virus adenovirus oncolytic virotherapy targeting immunogenic cell death αvβ6 integrin oncolytic adenovirus cancer immunotherapy multi-stage immunostimulatory arming HSV-1 clinical trials newcastle disease virus NDV cancer immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 type I interferon herpes simplex virus retargeted virus tropism retargeting tumor checkpoint inhibitor vaccination antigen-agnostic vaccination HER2 parvovirus tumor microenvironment combination therapy glioblastoma pancreatic cancer colorectal cancer measles virus vector engineering immune checkpoint blockade antitumor immune response delivery genetic modification biomarkers personalized oncolyticvirotherapy class I HLA immunosurveillance immunoediting oncogenic signaling RAS DNA methyltransferase inhibitor (DNMTi) viral mimicry epigenetic silencing adoptive T cell therapy CAR T cell pancreatic ductal adenocarcinoma vesicular stomatitis virus small molecule cancer immune therapy cancer therapy 3-0365-2549-1 3-0365-2548-3 Ilkow, Carolina S. edt Melcher, Alan edt Marchini, Antonio oth Ilkow, Carolina S. oth Melcher, Alan oth |
| language |
English |
| format |
eBook |
| author2 |
Ilkow, Carolina S. Melcher, Alan Marchini, Antonio Ilkow, Carolina S. Melcher, Alan |
| author_facet |
Ilkow, Carolina S. Melcher, Alan Marchini, Antonio Ilkow, Carolina S. Melcher, Alan |
| author2_variant |
a m am c s i cs csi a m am |
| author2_role |
HerausgeberIn HerausgeberIn Sonstige Sonstige Sonstige |
| title |
Oncolytic Virus Immunotherapy |
| spellingShingle |
Oncolytic Virus Immunotherapy |
| title_full |
Oncolytic Virus Immunotherapy |
| title_fullStr |
Oncolytic Virus Immunotherapy |
| title_full_unstemmed |
Oncolytic Virus Immunotherapy |
| title_auth |
Oncolytic Virus Immunotherapy |
| title_new |
Oncolytic Virus Immunotherapy |
| title_sort |
oncolytic virus immunotherapy |
| publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
| publishDate |
2022 |
| physical |
1 electronic resource (366 p.) |
| isbn |
3-0365-2549-1 3-0365-2548-3 |
| illustrated |
Not Illustrated |
| work_keys_str_mv |
AT marchiniantonio oncolyticvirusimmunotherapy AT ilkowcarolinas oncolyticvirusimmunotherapy AT melcheralan oncolyticvirusimmunotherapy |
| status_str |
n |
| ids_txt_mv |
(CKB)5680000000037759 (oapen)https://directory.doabooks.org/handle/20.500.12854/81172 (EXLCZ)995680000000037759 |
| carrierType_str_mv |
cr |
| is_hierarchy_title |
Oncolytic Virus Immunotherapy |
| author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField noLinkedField noLinkedField |
| _version_ |
1796651990425534464 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04278nam-a2201129z--4500</leader><controlfield tag="001">993544933204498</controlfield><controlfield tag="005">20231214133213.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202205s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5680000000037759</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/81172</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995680000000037759</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Marchini, Antonio</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Oncolytic Virus Immunotherapy</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (366 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, “Oncolytic Virus Immunotherapy”, summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical & internal medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncolytic viruses</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">combinatory therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">reovirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncolytic virus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adenovirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncolytic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">virotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeting</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunogenic cell death</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">αvβ6 integrin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncolytic adenovirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multi-stage</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunostimulatory</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">arming</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HSV-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical trials</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">newcastle disease virus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NDV</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-L1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CTLA-4</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">type I interferon</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">herpes simplex virus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">retargeted virus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tropism retargeting</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">checkpoint inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vaccination</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antigen-agnostic vaccination</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HER2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">parvovirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor microenvironment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">combination therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glioblastoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pancreatic cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">colorectal cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">measles virus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vector engineering</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint blockade</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antitumor immune response</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genetic modification</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">personalized oncolyticvirotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">class I HLA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunosurveillance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunoediting</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncogenic signaling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RAS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA methyltransferase inhibitor (DNMTi)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">viral mimicry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epigenetic silencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adoptive T cell therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CAR T cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pancreatic ductal adenocarcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vesicular stomatitis virus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">small molecule</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer immune therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer therapy</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2549-1</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2548-3</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ilkow, Carolina S.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Melcher, Alan</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marchini, Antonio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ilkow, Carolina S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Melcher, Alan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:46:34 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-05-14 21:41:54 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337792520004498&Force_direct=true</subfield><subfield code="Z">5337792520004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337792520004498</subfield></datafield></record></collection> |